AIMS: To test the efficacy and safety of varenicline as an aid to smoking cessation in methadone-maintained smokers. DESIGN: Multicenter, randomized, double-blind, placebo-controlled trial with random assignment to 12 weeks of varenicline 1 mg twice daily (n = 57) or matched placebo (n = 55), with in-person and telephone counseling. SETTING: Urban methadone programs in the Bronx, New York City, New York, USA. PARTICIPANTS: Methadonemaintenance patients, smoking ≥5 cigarettes/day, interested in quitting, stable in methadone treatment, without current Axis I psychiatric disorders, suicidal ideation or recent suicide attempts. MEASUREMENTS: Seven-day point prevalence abstinence verified by expired carbon monoxide (CO) < 8 parts per million at week 12 (primary outcome); carbon monoxide (CO)-verified abstinence, cigarettes/day, incidentAxis I psychiatric illness, suicidal ideation or serious adverse events (SAEs) at weeks 2, 4, 8, 12 or 24 (secondary outcomes). FINDINGS:Baseline demographic, smoking and clinical factors were similar between groups. Retention at 24 weeks was 90%. Subjects receiving varenicline were more likely than those receiving placebo to achieve abstinence (10.5 versus 0%, P = 0.03; effect size 10.5%, 95% confidence interval (CI) = 4.4-19.3%) and to reduce smoking (median five versus two cigarettes/day, P < 0.001) at 12 weeks. These effects were not maintained after drug treatment ceased. Incident psychiatric illness (OR= 0.84, 95% CI = 0.16, 4.4) and suicidality [odds ratio (OR) = 0.88, 95% CI 0.2, 3.9] were not different between groups. There were no psychiatric or cardiac SAEs. CONCLUSIONS:Varenicline can aid short-term smoking abstinence in methadone-maintained smokers.
RCT Entities:
AIMS: To test the efficacy and safety of varenicline as an aid to smoking cessation in methadone-maintained smokers. DESIGN: Multicenter, randomized, double-blind, placebo-controlled trial with random assignment to 12 weeks of varenicline 1 mg twice daily (n = 57) or matched placebo (n = 55), with in-person and telephone counseling. SETTING: Urban methadone programs in the Bronx, New York City, New York, USA. PARTICIPANTS: Methadone maintenance patients, smoking ≥5 cigarettes/day, interested in quitting, stable in methadone treatment, without current Axis I psychiatric disorders, suicidal ideation or recent suicide attempts. MEASUREMENTS: Seven-day point prevalence abstinence verified by expired carbon monoxide (CO) < 8 parts per million at week 12 (primary outcome); carbon monoxide (CO)-verified abstinence, cigarettes/day, incident Axis I psychiatric illness, suicidal ideation or serious adverse events (SAEs) at weeks 2, 4, 8, 12 or 24 (secondary outcomes). FINDINGS: Baseline demographic, smoking and clinical factors were similar between groups. Retention at 24 weeks was 90%. Subjects receiving varenicline were more likely than those receiving placebo to achieve abstinence (10.5 versus 0%, P = 0.03; effect size 10.5%, 95% confidence interval (CI) = 4.4-19.3%) and to reduce smoking (median five versus two cigarettes/day, P < 0.001) at 12 weeks. These effects were not maintained after drug treatment ceased. Incident psychiatric illness (OR= 0.84, 95% CI = 0.16, 4.4) and suicidality [odds ratio (OR) = 0.88, 95% CI 0.2, 3.9] were not different between groups. There were no psychiatric or cardiac SAEs. CONCLUSIONS:Varenicline can aid short-term smoking abstinence in methadone-maintained smokers.
Authors: A Eden Evins; Corinne Cather; Sarah A Pratt; Gladys N Pachas; Susanne S Hoeppner; Donald C Goff; Eric D Achtyes; David Ayer; David A Schoenfeld Journal: JAMA Date: 2014-01-08 Impact factor: 56.272
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Nina A Cooperman; Kimber P Richter; Steven L Bernstein; Marc L Steinberg; Jill M Williams Journal: Subst Use Misuse Date: 2015-01-05 Impact factor: 2.164
Authors: Andrea H Weinberger; Misato Gbedemah; Melanie M Wall; Deborah S Hasin; Michael J Zvolensky; Renee D Goodwin Journal: Addiction Date: 2017-12-19 Impact factor: 6.526
Authors: Stacey C Sigmon; Mollie E Miller; Andrew C Meyer; Kathryn Saulsgiver; Gary J Badger; Sarah H Heil; Stephen T Higgins Journal: Addiction Date: 2016-01-23 Impact factor: 6.526